*Disclaimer

ALTERITY THERAPEUTICS LIMITED (ASX: ATH)

🔗 📄 📈

ATH: ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

ALTERITY THERAPEUTICS LIMITED

2023-05-30 13:32:00

ATH: US patent grant and license agreement

ALTERITY THERAPEUTICS LIMITED

2023-03-14 10:42:00

ATH: First Patient Enrolled in Europe in Phase II Clinical trial

ALTERITY THERAPEUTICS LIMITED

2023-03-08 09:19:00

ATH: Regulatory approval for Phase II trial in France and Austria

ALTERITY THERAPEUTICS LIMITED

2023-02-16 12:30:00

ATH: ATH434 Clinical Trial Launched in Italy

ALTERITY THERAPEUTICS LIMITED

2023-01-25 09:50:00

ATH: ATH434 Clinical Trial Launched In The US

ALTERITY THERAPEUTICS LIMITED

  1. Alterity Therapeutics has launched a Phase 2 clinical trial of ATH434 for the treatment of individuals with Multiple System Atrophy (MSA).
  2. "The opening of enrol lment in the U.S. is a major milestone for this trial and we are now actively recruiting patients in three regions: Europe, Asia-Pacific, and the U.S."
  3. Vanderbilt University Medical Center in Nashville, Tennessee is the first U.S. trial site.

2023-01-09 11:40:00

ATH: New US patent for compounds to treat neurodegeneration

ALTERITY THERAPEUTICS LIMITED

  1. Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson’s and Alzheimer’s.
  2. Provides Alterity with 20 years of exclusivity.
  3. Expands its intellectual property estate for treating major neurodegenerative diseases.

2022-12-29 11:56:00